Dr. Fine is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3801 Miranda Ave
Palo Alto, CA 94304Phone+1 650-493-5000
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1999 - 2000
Harvard Medical SchoolClass of 1996
Certifications & Licensure
CA State Medical License 1997 - 2025- American Board of Internal Medicine Hematology
Clinical Trials
Publications & Presentations
PubMed
- 42 citationsPhase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer.Daniel C. Danila, Russell Z. Szmulewitz, Ulka N. Vaishampayan, Celestia S. Higano, Ari David Baron
Journal of Clinical Oncology. 2019-11-05 - 14 citationsSingle cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties.Ayse M. Ovacik, Ji Li, Marie Lemper, Dimitry M. Danilenko, Nicola J. Stagg
Mabs. 2019-02-01 - 447 citations89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancerFrederike Bensch, Elly L van der Veen, Marjolijn N. Lub-de Hooge, Annelies Jorritsma-Smit, Ronald Boellaard
Nature Medicine. 2018-11-26
Journal Articles
- 89Zr-Atezolizumab Imaging as a Non-Invasive Approach to Assess Clinical Response to PD-L1 Blockade in CancerBernard Fine, MD, Nature
Grant Support
- Gene Expression Patterns In Acute Lymphoblastic LeukemiaNational Cancer Institute2002–2003
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
